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NullipotencyEmbryonal carcinoma (EC) cells, which are considered to be malignant counterparts of embryonic stem cells,
comprise the pluripotent stem cell component of teratocarcinomas, a form of testicular germ cell tumors
(GCTs). Nevertheless, many established human EC cell lines are nullipotent with limited or no capacity to differ-
entiate under normal circumstances. In this study, we tested whether an over-expression of Yamanaka's
reprogramming factors OCT4, SOX2, c-MYC and KLF4 might enable differentiation of the human nullipotent EC
cells N2102Ep. Using OCT4 knockdown differentiated N2102Ep cells, we are able to derive reprogrammed
N2102Ep cell lines. The induced pluripotency of N2102Ep allows the cells to differentiate toward neural lineage
by retinoic acid; the expression of SSEA3 and SSEA4 is down-regulated, whereas that of neural surfacemarkers is
up-regulated. Consistent with the up-regulation of neural surface markers, the expression of the master
neuroectodermal transcription factor PAX6 is also induced in reprogrammed N2102Ep. We next investigated
whether PAX6 might induce spontaneous differentiation of nullipotent stem cells N2102Ep. However, while an
ectopic expression of PAX6 promotes differentiation of NTERA2, it induces cell death in N2102Ep.We nevertheless
ﬁnd that upon induction of retinoic acid, the reprogrammed N2102Ep cells form mature neuronal morphology
similar to differentiated pluripotent stem cells NTERA2 as determined by TUJ1 expression, which is absent in
N2102Ep parental cells. Altogether,we conclude that the nullipotent state of human EC cells can be reprogrammed
to acquire a more relaxed state of differentiation potential by Yamanaka's factors.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Testicular germ cell tumors (GCTs) are themost commonmalignant
cancer in youngmen between 20 and 40 years old [1,2]. This pattern of
the incidence occurring in young men is different from incidences of
most cancers, which increase with age. One factor that might implicate
the early onset of testicular GCTs is its embryonic cell origin from
primordial germ cells (PGCs) which are recognized in human embryos
at weeks 5–6. Seminoma and non-seminoma GCTs are the most
predominant testicular GCTs. Seminoma is composed of cells that resem-
ble PGCs,whereas non-seminoma testicular GCTmay contain embryonal
carcinoma (EC) cells together with elements of teratoma (togethernic stem; iPS, induced pluripo-
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ongtrakoongate).with EC cells, referred to as teratocarcinoma), yolk sac carcinoma
and choriocarcinoma. The EC cells of teratocarcinoma are well
recognized as pluripotent cancer stem cells capable of differentiating
into somatic cells of all three embryonic germ layers [2]. Nevertheless,
some GCTs are composed entirely of EC cells which have apparently
lost their capacity for differentiation. Such apparently “nullipotent” EC
cells may arise by mutation during cancer progression since a reduced
capacity to differentiate would provide the cells with a selective growth
advantage, leading to a more aggressive cancer phenotype [3].
The mechanism by which nullipotent EC cells arise is unknown.
Somemouse EC cell lines established in vitro are nullipotent [4]. Several
studies in which such nullipotent mouse EC cells were fused to somatic
cells resulted in hybrid cells with pluripotent characteristics, suggesting
that nullipotency results from amutation leading to the loss of function
of gene(s) required for differentiation [5–8]. Amajority of human EC cell
lines are nullipotent [9–12]. For example, most human EC cell lines do
not differentiate in response to retinoic acid [13], which induces
differentiation of mouse EC cells and the pluripotent human EC cell
line NTERA2 [10]. Nevertheless, hybrids between a nullipotent human
EC cell line N2102Ep and the pluripotent NTERA2 were capable of
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differentiate into mature neurons [14]. This ﬁnding suggests that the
nullipotent state of human EC cells, like that of nullipotent mouse EC
cells, results from the loss of some key differentiation inducers.
While the hybrid experiments point to mutations in the nullipotent
EC cells limiting their capacity for differentiation, the nature of these
mutations or the genes affected are unknown. Human embryonic
stem (ES) cells in culture have been shown to acquire a variety of
non-random genetic and epigenetic changes that also occur in human
EC cells [15–17]. Hence, these genetic and/or epigenetic changes may
arise because they confer similar selective advantages to such variant
stem cells, whether in vitro or in vivo. In the case of N2102Ep human
EC cells, which do not differentiate in response to retinoic acid, the
cells nevertheless are capable of a response to retinoic acid since. For ex-
ample, retinoic acid receptor beta (RARB) is induced in these cells by
retinoic acid as it is in pluripotent NTERA2 EC cells [14,18]. Therefore,
the block of differentiation must be downstream of RARB. One possi-
bility might be a failure to up-regulate the expression of key master
developmental regulators such as PAX6, which has been shown to
directly suppress the expression of stem cell-associated genes in
human ES cells [19], through genetic mutation of their regulatory
or coding sequences. Another possibility is the genetic and/or epige-
netic barrier within nullipotent EC cells, which does not allow the
cells to differentiate. Such a barrier to differentiation has been sug-
gested for mouse EC cells, which were unable to be reprogrammed by
nuclear transfer [20].
Despite their nullipotency, human EC cell lines such as N2102Ep
express the characteristic surface antigen patterns that characterize
both human pluripotent EC and ES cells [21]. They also have gene
expression proﬁles similar to human ES cells, including similar
expression levels of pluripotency-associated genes such as those
used for the generation of human induced pluripotent stem (iPS)
cells (e.g. OCT4, NANOG, SOX2, LIN28, and KLF4) [22–25]. In the present
study, we aimed to test whether the nullipotent stem cells N2102Ep
could be induced to differentiate by reprogramming via Yamanaka's
factors. We ﬁnd that by reprogramming differentiated N2102Ep cells,
which were generated by OCT4 knockdown, we are able to derive
reprogrammed N2102Ep cell lines which show an ability to differenti-
ate into neural lineage by induction of retinoic acid. Our study therefore
suggests that the nullipotent state might be maintained in part by
epigenetic mechanism(s), which suppress differentiation of nullipotent
stem cells.2. Materials and methods
2.1. Cell culture
Human EC cell lines N2102Ep [26] and NTERA2 [9] were grown in
DMEM with 10% FBS (Invitrogen), and placed at 37 °C under a
humidiﬁed atmosphere of 10% CO2 incubator. N2102Ep and
NTERA2 were passaged every 3 days using 0.25% and 0.05% trypsin, re-
spectively. Reprogrammed N2102Ep cell lines RepN5 and RepN13,
whichwere generated by iPS reprogramming (see below),were cultured
in human ES culture condition, i.e. Knockout-DMEM supplemented with
20% Knockout-SerumReplacement, 1× non-essential amino acids, 1mM
glutamine, 0.1mMbeta-mercaptoethanol and4ng/ml bFGF (Invitrogen)
seeded on 6 × 103 cells/cm2 mitomycin C-treated MF-1 mouse embry-
onic ﬁbroblasts (MEFs), and placed at 37 °C under a humidiﬁed atmo-
sphere of 5% CO2 incubator. Cells were passaged every 5–7 days using
collagenase type IV (Invitrogen) and scraping with glass-beads
(Sigma). NTERA2 and parental N2102Ep harboring OCT4 inducible
shRNAi system (see below) were cultured under this human ES con-
dition for differentiation study. To induce differentiation, the culture
medium was supplemented with 10 μM of all-trans retinoic acid
(Sigma).2.2. Generation of differentiatedN2102Ep by OCT4 knockdownand induced
pluripotency
N2102Ep cell line harboring tetracycline repressor (TetR) and short
hairpin interfering RNA targeting OCT4 was established by transfecting
pCAG-TetRnls-IRES-puromycin and pSuperior-Neo (Oligoengine) con-
taining OCT4 siRNA [27]. Principally, inside the cells the plasmid
pCAG-TetRnls-IRES-puromycin constitutively encodes the tetracycline
repressor TetR, which will in turn bind to the shRNA promoter region
of the plasmid pSuperior-Neo in the absence of doxycycline, thereby
suppressing shRNA expression. In the presence of doxycycline, which
is a ligand of TetR, the repressor is then evicted from the shRNApromot-
er leading to an expression of shRNA [27]. Stable transfected N2102Ep
colonies were selected and expanded using 3 μg/ml puromycin and
750 μg/ml G418 (Invitrogen). Reverse transcription quantitative
polymerase chain reaction and western blotting were employed to val-
idate the expression of OCT4 knockdown in cells grownwith or without
1 μg/ml doxycycline.
To generate iPS cells, N2102Ep OCT4 knockdown cells were treated
with 1 μg/ml doxycycline for two weeks to derive differentiated cells.
The medium was changed every 3 days. The expression of SSEA3 and
SSEA1 and the cloning efﬁciency test were performed to assure a
complete differentiation of N2102Ep. Differentiated OCT4 knockdown
cells were then transfected by PmeI-linearized four-in-one plasmid
over-expressing OCT4, SOX2, c-MYC and KLF4 jointly expressed by 2A
peptides togetherwith puromycin resistant gene and a redﬂuorescence
protein (RFP) (Supplementary Fig. 1). Transfected cells were immediate-
ly transferred to human ES culture condition. Colonies stably expressing
the reprogramming factors, as indicated by RFP-positive expression,
were manually selected [28]. Two reprogrammed N2102Ep (RepN)
clones were subsequently tested for their differentiation potential, i.e.
clones RepN5 and RepN13. The expression of SSEA3 and SSEA4was con-
ﬁrmed in the reprogrammed N2102Ep cell lines by the ﬂow cytometry
analysis. The expression of stem cell-associated genes OCT4 and NANOG
was conﬁrmed by qPCR.
2.3. Establishment of PAX6 over-expressing N2102Ep and NTERA2 cell lines
The human PAX6 coding sequence was ampliﬁed from a plasmid
containing PAX6 gene (kindly provided by Prof. Su-Chun Zhang, Univer-
sity of Wisconsin, Madison). A FLAG tag-containing primer was used to
add thepeptide at the 5′-position of the coding sequence to allowdetec-
tion of the transgene by anti-FLAG antibody (Sigma). The FLAG-PAX6
DNA fragment was gel-puriﬁed using a DNA extraction kit from Qiagen.
A red ﬂuorescence protein (RFP) encoding gene of pCAG-RFP-IRES-
puromycin was excised using XhoI and NotI, and was replaced by the
FLAG-PAX6 DNA fragment. The plasmid pCAG-FLAG-PAX6-IRES-
puromycin was then transfected into either N2102Ep or NTERA2 to es-
tablish the PAX6 over-expressing cell lines using electroporation. Brieﬂy,
human EC cells were dissociated using 0.25% trypsin. One million cells
were then transfected with 3 μg of PvuI-linearized plasmid DNA. pCAG-
RFP-IRES-puromycin was also separately transfected in the parental
N2102Ep and NTERA2 to establish control cell lines. The transfectants
were immediately plated in DMEM-F12 plus 10% FBS (Invitrogen).
Three days after the transfection, 3 μg/ml puromycin (Sigma) was
added to the culture medium to select colonies which were resistant to
the antibiotic. Western blotting was employed to test PAX6 over-
expression in the human EC cell lines.
2.4. Western blotting
Cell pelletswere resuspended in RIPA buffer (150mMNaCl, 1% (w/v)
sodium deoxycholate, 25 mM Tris–Cl pH 8.0, 1% (v/v) NP-40, and 0.1%
(w/v) SDS, protease inhibitor cocktails), and were subjected to
soniﬁcation. Protein concentrationwas determinedusing a bicinchoninic
acid (BCA) protein assay kit (Thermo Scientiﬁc). Forty micrograms of
Fig. 1. Inducible silencing of OCT4 leads to a massive differentiation of human nullipotent EC cells N2102Ep. (A) RT-qPCR analysis of OCT4 in OCT4-knockdown N2102Ep. Doxycycline
(Dox) treatment leads to down-regulation of OCT4 expression. Expression levels were normalized to ACTB, and are shown relative to no doxycycline treatment. Data are
shown as mean ± SD; n = 3. (B) Western blot analysis of OCT4 shows that doxycycline treatment leads to a depletion of OCT4 level. A representative image of two biologically
independent experiments is shown. (C) Phase contrast images of N2102Ep showing that doxycycline treatment results in differentiated morphology of the cells. Scale bars =
50 μm. (D) Flow cytometric analysis of the stem cell marker SSEA3 and a marker of trophectodermal differentiation SSEA1. (E) Cloning efﬁciency is lost by silencing of OCT4.
Data are shown as mean ± SD; n = 3.
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membrane (Invitrogen). Antibodies for western blotting are as follow-
ed; Rabbit polyclonal antibody against PAX6 (PA1-801) from Thermo
Scientiﬁc; mouse monoclonal antibody against OCT4 (sc-101534)
from Santa Cruz; mouse monoclonal antibody against ACTB (A5316)
from Sigma.2.5. Reverse transcription quantitative polymerase chain reaction
(RT-qPCR)
RNA was extracted using TRIzol reagent (Invitrogen), and was
DNase-treated using TURBO DNA-free (Ambion). Complementary
DNA synthesis was performed with 1 μg RNA. qPCR was carried on by
using SYBR Green JumpStart Taq ReadyMix (Sigma) in a total volume
of 20 μl each well with an iCycler iQ system (Biorad). Gene expression
was normalized by the expression level of ACTB. Primer sequences are
available upon request.2.6. Cloning efﬁciency assay
Cells were washed once with PBS, and were disaggregated to
single-cell level using 0.25% trypsin. Cells were seeded at 500 cells
with DMEM-F12 with 10% FBS, in a six-well plate. After a two-
week culture, cells were washed once with PBS and ice-cold
methanol, respectively. Cells were ﬁxed with 1 ml of the methanol
for 15 min at room temperature. The methanol was removed, and
cells were incubated with 1 ml of a crystal violet solution (0.4% (w/v)
in methanol) for another 15 min. Unstained crystal violet was washed
off by water. The plates were dried and were counted for colony
numbers.2.7. Flow cytometry
Flow cytometry was performed as previously described [21].
Brieﬂy, cultured cells were harvested by trypsinization. One hundred
thousand cells in 100 μl PBS with 10% FCS were incubated with pri-
mary monoclonal antibodies including P3X (negative control),
SSEA3, SSEA4, A2B5, B159, Vinis56 and Vin2Pb22 at 1:10 dilution
for 30 min. Cells were washed and incubated with FITC-conjugated
secondary antibody (Jackson Laboratory). Cell surface expression
was then analyzed by a Cyan bench-top ﬂow cytometer (Dako
Cytomation).
2.8. Immunoﬂuorescence staining
N2102Ep, NTERA2 and reprogrammed N2102Ep cells were grown
in a 24-well chamber with retinoic acid induction for three weeks,
and were ﬁxed with 4% PFA. Fixed cells were permeabilized with
0.5% Triton-X 100, and were incubated with monoclonal rabbit
anti-TUJ1 (MRB-435P, Covance). A secondary antibody conjugated
with FITC (Santa Cruz) was then used for visualization under an
InCell Analyzer ﬂuorescence microscope workstation system (GE
Healthcare).
3. Results
3.1. Ectopic expression of reprogramming factors induces cell death in
nullipotent N2102Ep EC cells
We ﬁrst asked whether the nullipotent state can be destabilized by
an ectopic expression of Yamanaka's factors OCT4, SOX2, c-MYC and
KLF4, to acquire differentiation potential in N2102Ep, albeit already
Fig. 2. Establishment of reprogrammed N2102Ep cells by Yamanaka's factors. (A) Day 14
and day 28 of reprogrammed N2102Ep cells. Undifferentiated N2102Ep was treated by
doxycycline to knockdown OCT4. Differentiated N2102Ep was then transfected with the
reprogramming plasmid, and seeded under human ES culture condition. RFP-positive
colonies indicate successful establishment of reprogrammed N2102Ep colonies. The
arrow indicates the RFP-positive colony at day 14. (B) Doxycycline treatment of
reprogrammed N2102Ep leads to differentiation of the cells, indicating that the
reprogrammed N2102Ep cells were derived from doxycycline inducible OCT4 knockdown
N2102Ep cell line. Scale bars = 100 μm.
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stem cells [22,23]. A single plasmid driving expression of the four factors
under CAG promoter (Supplementary Fig. 1A), was transfected into
N2102Ep.With the use of an internal ribosome entry site (IRES), a puro-
mycin resistant gene and a gene encoding RFP are also transcribed
under the same CAG promoter together with the four factors [28]. We
found that, however, RFP-positive cells failed to proliferate, and could
not survive eventually after puromycin selection (Supplementary
Fig. 1B). On the other hand, a selection of puromycin resistant colonies
of N2102Ep transfected with pCAG vector encoding only puromycin
resistant gene and RFP, but not the reprogramming factors, yielded sta-
ble N2102Ep cell line expressing RFP (Fig. 5B, see below). In addition,
transfection of the reprogramming plasmid into the pluripotent
NTERA2 cells enabled puromycin selection of proliferating RFP-
positive cells (Supplementary Fig. 1B). These results indicate that
over-expression of the reprogramming factors is highly toxic to
N2102Ep but not to NTERA2.
3.2. Reprogramming of nullipotent N2102Ep EC cells by induced pluripotency
The failure to establish undifferentiated nullipotent stem cells
N2102Ep over-expressing the reprogramming factors might be due
to genetic and/or epigenetic incompatibility of the stem cells to
respond to the transgene expression. We have previously reported
that silencing of OCT4 by transient siRNA leads to differentiation of
N2102Ep at high efﬁciency [29]. To ascertain whether differentiated
N2102Ep cells are permissive for reprogramming, we induced differ-
entiation of N2102Ep nullipotent stem cells with an inducible shRNA
(shRNAi) system to knockdown OCT4 upon doxycycline treatment
[27]. Treatment of OCT4 knockdown N2102Ep cells with doxycycline
led to down-regulation of OCT4 as determined by qPCR and western
blot analysis (Fig. 1A–B). Morphological examination of OCT4
knockdown N2102Ep cells revealed a differentiated phenotype of
doxycycline-treated culture (Fig. 1C). In addition, silencing of OCT4
led to a loss of SSEA3 and a gain of SSEA1 representing human plurip-
otent stem cell and differentiation markers, respectively (Fig. 1D).
Moreover, OCT4 knockdown completely abolished the appearance
of stem cell colonies (Fig. 1E). These results therefore indicate an
efﬁcient and massive differentiation of nullipotent N2102Ep cells
by inducible silencing of OCT4.
We next determined whether iPS reprogramming of OCT4 knock-
down differentiated N2102Ep would yield stem cells with an ability of
differentiation similar to pluripotent stem cells. To this end, OCT4 ex-
pression was depleted by repeated treatment with doxycycline for
more than two weeks to ensure loss of undifferentiated stem cells
(Fig. 1C–E). The differentiated N2102Ep cells were transfected by the
reprogramming plasmid, and were directly seeded on MEFs with
human ESmedium. RFP-positive colonieswere observed approximately
2 weeks after seeding (Fig. 2A), which were then picked at day 30 to
expand RFP-positive cells. These reprogrammedN2102Ep cell lines pos-
sess similar morphology to human ES cells and express SSEA3, SSEA4,
OCT4 and NANOG (Figs. 3 and 4 and Supplementary Figs. S3 and S4),
which aremarkers of human ES cells [30]. Speciﬁcally, the reprogrammed
N2102Ep cells express SSEA3 at 60–70% and SSEA4 at 90–95% of total
population; the former has been shown to be the most sensitive marker
of human ES cell state [21]. In addition, similar to their parental cells,
they were able to differentiate following exposure to doxycycline
(Fig. 2B).
3.3. Induced pluripotency enables neural differentiation of reprogrammed
nullipotent N2102Ep EC cells
To elucidate whether reprogrammed N2102Ep cells had gained a
capability of differentiation in response to retinoic acid similar to their
pluripotent counterpart NTERA2, the cells were tested for surfacemark-
er and gene expression in response to retinoic acid treatment. InN2102Ep parental control cells, retinoic acid treatment caused no signif-
icant change of expression of surface markers conﬁrming that they do
not differentiate in response to retinoic acid exposure (Fig. 3 and
Supplementary Fig. 2). In contrast to their parental N2102Ep control
cells, two reprogrammed N2102Ep cell lines, RepN5 and RepN13,
expressed a lower level of SSEA3 and SSEA4. Further, retinoic acid treat-
ment resulted in marked down-regulation of these stem cell markers
(Fig. 3 and Supplementary Figs. 3–4). Also, approximately 10–20% of
cells expressing neural differentiation markers A2B5, B159, VINIS56
and VIN2Pb22 were observed in RepN5 and RepN13 on day 21 of
retinoic acid treatment (Fig. 3 and Supplementary Figs. 3-4). By compar-
ison, in NTERA2 more than 50% of cells expressing those markers were
observed as soon as day 7 of retinoic acid treatment (Fig. 3 and
Supplementary Fig. 5). This result suggests that the reprogrammed
N2102Ep cell lines RepN5 and RepN13, unlike their parental N2102Ep,
differentiate into neural lineage in response to retinoic acid, albeit
with a slower effect and a lower degree of differentiation compared
with NTERA2.
We next asked whether retinoic acid treatment would down-
regulate the expression of stem cell-associated genes as well as up-
regulate differentiation-associated genes in RepN5 and RepN13. The
result shows that, consistent with the ﬂow cytometry data, the expres-
sion of OCT4 and NANOG was not down-regulated by retinoic acid in-
duction in N2102Ep control (Fig. 4). Moreover, differentiation-
associated genes PAX6, NEUROD1 and HOXB9were not up-regulated in
the control parental cells. However, GATA6 showed an induction about
Fig. 3.Retinoic acid induces expression of cell surfacemarkers characteristic of neural differentiation in reprogrammedN2102Ep. Cells were induced to differentiate by 10 μMretinoic acid
for a period of three weeks. Expression of surface markers was determined by ﬂow cytometry. Expression of all surface markers including the stem cell-associated SSEA3 and SSEA4, and
neural differentiation-associated A2B5, B159, Vinis56 and Vin2PB22, is not altered upon retinoic acid induction of N2102Ep. In contrast, RepN5, RepN13 and NTERA2 down-regulate
expression of SSEA3 and SSEA4, whereas that of A2B5, B159, Vinis56 and Vin2Pb22 is up-regulated by retinoic acid. Data are shown as mean ± SD; n = 3. * p b 0.05.
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genes encoding retinoic acid receptors, we found that the expression
level of retinoic acid receptor beta (RARB) was induced by retinoic
acid treatment in N2102Ep (Supplementary Fig. S6), supporting our
previous ﬁnding [14]. However, the expression level of RARA and
RARG was not altered by retinoic acid treatment. Thus, in the absence
of a down-regulation of stem cell-associated genes and an unperturbed
expression of stem cell surface markers, these results indicate that the
nullipotent stem cells N2102Ep fail to undergo differentiation in
response to retinoic acid.
In RepN5, RepN13 and NTERA2, where the expression level of cell
surface markers associated with the stem cell state was reduced in
response to retinoic acid (Fig. 3), the expression of OCT4 was also
down-regulated by retinoic acid treatment (Fig. 4). However, in
contrast to NTERA2, the expression of NANOG was not decreased in
RepN5 and RepN13 by retinoic acid treatment. Similar to the parental
nullipotent N2102Ep, the expression level of RARB but not RARA or
RARG was induced by retinoic acid in RepN5, RepN13 and NTERA2
(Supplementary Fig. S6). Interestingly, the expression of differentiation-
associated genes PAX6 and NEUROD1 (neural differentiation), HOXB9
(mesodermal differentiation) and GATA6 (endodermal differentiation)
was also up-regulated in RepN5, RepN13 and NTERA2. Therefore,
consistent with the surface marker expression, these results suggest
that the reprogrammed N2102Ep cells undergo differentiation in
response to retinoic acid, particularly into neural lineage as determined
by the expression of A2B5, B159, VINIS56, VIN2Pb22, PAX6 and
NEUROD1.3.4. Differential response of PAX6 over-expression in nullipotent N2102Ep
and pluripotent NTERA2 EC cells
Since the reprogrammed N2102Ep cell lines, but not their parental
control cells, can be induced to differentiate into neural lineage based
on surfacemarker and gene expression (Figs. 3 and 4), we askedwheth-
er a simple over-expression of PAX6might induce neural differentiation
ofwild-typeN2102Ep nullipotent stem cells.We chose to test the role of
PAX6 in neural differentiation induction because (1)we detected an up-
regulationofneural surfacemarkers, (2) PAX6 is induced in reprogrammed
N2102Ep cells by retinoic acid, and (3) an over-expression of PAX6 has
been shown to spontaneously and efﬁciently induce differentiation of
human ES cells [19]. In contrast to PAX6, the role of NEUROD1, HOXB9 or
GATA6 in spontaneous differentiation of human ES cells has never been
reported.
We transfected a plasmid containing PAX6 coding sequence under
CAG promoter or a control parental plasmid (CAG-RFP) into nullipotent
and pluripotent EC cells N2102Ep and NTERA2, respectively. Western
blot analysis of FLAG tag revealed the expression of the ectopic PAX6
over-expression in the two cell lines (Fig. 5A). However, upon long-
termed selection of puromycin, N2102Ep cells over-expressing PAX6
were completely detached from culture. On the other hand, we were
able to establish NTERA2 cell lines over-expressing PAX6 (Fig. 5B).
This result indicates that PAX6 might be very toxic to N2102Ep. Flow
cytometry analysis of NTERA2 over-expressing PAX6 shows that the
PAX6 transgene down-regulates the expression of the stem cell
marker SSEA3, whereas that of the neural differentiation marker
Fig. 4. Expression of genes involved in differentiation is up-regulated in reprogrammedN2102Ep by retinoic acid. Cells were induced to differentiate by 10 μM retinoic acid for a period of
three weeks. Gene expression was determined by RT-PCR. The expression of PAX6, NEUROD1, HOXB9 and GATA6 is markedly induced by retinoic acid in RepN5, RepN13 and NTERA2, but
not in N2102Ep. Data are shown as mean ± SD; n = 3. *p b 0.05.
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that PAX6 over-expression up-regulates the expression of neural
speciﬁc genes (Fig. 5D) supporting the role of PAX6 in neural induction
of human pluripotent stem cells [19]. These results thus indicate that an
over-expression of PAX6 is not compatible with survival of wild-type
N2102Ep, but induces differentiation of the pluripotent stem cells
NTERA2.3.5. Differentiation of reprogrammed N2102Ep into mature neurons
The hybrid cell line C10 established from NTERA2 and N2102Ep
has been shown to be incapable of the generation of mature neurons
[14]. Since surface markers involved in neural differentiation, i.e.
A2B5, B159, VINIS56 and VIN2Pb22 (Fig. 3) as well as genes involved
in neural differentiation (Fig. 4) were induced in RepN5 and RepN13
by retinoic acid treatment, an immunostaining was performed using
TUJ1 antibody to test whether mature neurons would be induced by
retinoic acid from the reprogrammed RepN5 and RepN13 cells. The
result shows that RepN5 and RepN13 generated from iPS
reprogramming produced TUJ1-positive cells indicating the presence
of mature neurons upon retinoic acid treatment (Fig. 6). This neuronal
differentiation was not seen in the control N2102Ep. Altogether,
these results suggest that RepN5 and RepN13 are able to be induced
to differentiate into mature neurons similar to those of NTERA2
in vitro, and that the iPS reprogramming can alter the nullipotent
state of N2102Ep into a more relaxed stem cell state with a capability
of differentiation.4. Discussion
Although the molecular and cellular biology of human EC cells has
been studied for more than three decades, the mechanism(s) behind
nullipotency, an operational deﬁnition used to describe stem cells that
appear to have lost the capacity to differentiate, has been elusive. By
using cell fusion techniques, several independent observers have pro-
posed that the nullipotency is conferred by genetic mutation of a
gene(s) involved in differentiation, leading to the attenuation of EC
cells to differentiate [5–8,14].
To further examinewhether the failure of N2102Ep EC cells to differ-
entiate could be due to epigenetic suppression of other critical regulato-
ry genes, we attempted to over-express the set of Yamanaka's factors,
i.e. OCT4, SOX2, c-MYC and KLF4, used for reprogramming somatic
cells to a pluripotent state. However, direct transfection of the plasmid
encoding these four factors into undifferentiated nullipotent stem cells
N2102Ep failed to establish a stable cell line, although we were able to
generateNTERA2 EC cells over-expressing these reprogramming factors
(Supplementary Fig. 1). Nevertheless, after N2102Ep EC cells were in-
duced to differentiate by knocking down the expression of OCT4 by an
inducible shRNA system, we found that the resulting differentiated
cells could be reprogrammed back to an undifferentiated, EC-cell like
state by over-expression of the four factors.
Down-regulation of SSEA3, SSEA4 and OCT4 and up-regulation of
A2B5, B159, VINIS56, VIN2Pb22, PAX6 and NEUROD1 upon retinoic acid
induction suggest that the reprogrammedN2102Ep, unlike their parental
cells, possesses an ability to differentiate into neural lineage (Figs. 3–4).
Moreover, in contrast to the N2102Ep–NTERA2 hybrid experiment
Fig. 5. PAX6 induces cell death of N2102Ep but promotes neural differentiation of NTERA2. (A) Western blot analysis of the FLAG tagged PAX6 transgene in human EC cells NTERA2 and
N2102Ep containing an empty plasmid or FLAG-tagged PAX6. (B) Phase contrast images of NTERA2 andN2102Ep over-expressing PAX6 upon a long-termed selection of puromycin. Scale
bars= 100 μm. (C) Flow cytometric analysis of the stem cell marker SSEA3 and a neural differentiation marker A2B5 of NTERA2 transfected with an empty plasmid or with FLAG-tagged
PAX6. Upper; Representative histograms. Lower; bar graph derived from three independent experiments. (D) Gene expression analysis was performed by RT-qPCR using stem cell- and
neural-associated genes in NTERA2 over-expressing PAX6. Note that primers for PAX6 are speciﬁc to its 3′UTR of endogenous but not ectopic PAX6 transcript. Data are shown as
mean ± SD; n = 3.
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Yamanaka's factors resulted in the generation of TUJ1-positive cells
from the reprogrammed N2102Ep (Fig. 6). Although the parental
N2102Ep cells maintain high expression levels of SSEA3, SSEA4 and
OCT4 similar to the reprogrammed N2102Ep cells when cultured under
human ES cell culture condition (Figs. 3-4), unlike their reprogrammed
counterparts they do not differentiate by retinoic acid treatment.
These results suggest that the culture condition alone, without iPS
reprogramming, is not sufﬁcient to allow the parental N2102Ep cells
to differentiate. Together, these results suggest that epigenetic changes
might play an important role for the nullipotency of N2102Ep cells
during tumor evolution and progression.
Retinoic acid receptor gamma (RARG) has been reported to play a
major role in differentiation of NTERA2 and its retinoic acid resistant
subclones [31–33]. We have previously shown that the hybrid cell line
C10, which was generated by fusion between NTERA2 and N2102Ep,
expresses RARG and RARB at similar levels compared to its parental
cell lines, and that expression level of RARB is also induced by retinoic
acid in NTERA2, N2102Ep and C10 [14]. We found that the expression
pattern of RARA, RARB, RARG is similar between the reprogrammed
N2102Ep cell lines RepN5 and RepN13 and their parental nullipotent
N2102Ep cells (Supplementary Fig. 6). Therefore, the differentiation
potential of the reprogrammedN2102Epmight be independent of path-
ways involving retinoic acid receptors.
Several studies have suggested that iPS cells might retain a certain
degree of epigenetic memory similar to somatic cells from which they
are derived from [34–37]. This retention of epigenetic memory mightinvolve histone modiﬁcation [36] and DNA methylation [37]. It might
be possible that a germline-speciﬁc epigenetic memory might still per-
sist in wild-type nullipotent N2102Ep cells [38], and that the germline
memory might be erased in OCT4-knockdown differentiated cells.
Therefore, the differentiated N2102Ep cells are now compatible with
iPS reprogramming, which allows the differentiated cells to be
reprogrammed into cells more similar to pluripotent EC cells than to
nullipotent EC cells.
EC and ES cells have been shown to possess different epigenetic pro-
ﬁles. A novel assay namely nucleosome enzyme-linked immunosorbent
assay (NU-ELISA) has been developed to quantify global levels of his-
tone modiﬁcations in ES and EC cells [39]. The study has shown that
mouse EC cells contain level of H3K4me1 at 10-fold less than mouse
ES cells, whereas levels of H3K9me1, H3K9me3 and H3K79me2 are
higher in EC cells than ES cells. By comparing genome-wide occupancy
of H3K4me3 and H3K27me3, Robertson and colleagues have revealed
differences in occupancy of the two histone marks between human ES
and EC cells, particularly at bivalent domains [40]. The authors also uti-
lized methyl CpG-binding domain protein-high throughput sequencing
(MBD-seq) to compare enrichment of MBD, which represents the
presence of DNA methylation, in human ES and EC cells. Interestingly,
the analysis shows that the patterns of MBD binding are remarkably
different in the two cell types. Moreover, human ES cells possess higher
levels of MBD binding at gene body than human EC cells [40]. The
discrepancy of DNA methylation proﬁles in human ES and EC cells
might be due to a germline-like state of EC cells, which has undergone
global DNA demethylation [41–44]. To support this notion, biallelic
Fig. 6. Reprogrammed N2102Ep terminally differentiates into mature neurons. Cells were
induced to differentiate by 10 μM retinoic acid up to three weeks. Cells were ﬁxed and
stained for TUJ1, which is a marker of terminally differentiated neurons. Scale bars =
50 μm.
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NTERA2 compared with human ES cells [45], although global DNA
methylation proﬁles of NTERA2 and human ES cells closely resemble
each other [46].
In conclusion, our study indicates that nullipotent EC cells can be
reprogrammed to acquire an ability to differentiate by Yamanaka's fac-
tors. Since nullipotent EC cells have been suggested as the cancer stem
cells with a strong genetic inﬂuence, this ﬁnding suggests that the
nullipotent statemight bemaintained not only by the genetic inﬂuence,
but also by other abnormalities such as an epigenetic instability.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.07.013.Acknowledgements
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